Description：ELISA for the detection of bispecific antibody Elranatamab in human serum and plasma.
Lead time for this kit is 5 weeks.
About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.Elranatamab is a bispecific antibody immunotherapy designed to bind to BCMA, which is highly expressed on the surface of multiple myeloma （MM） cells, and the CD3 receptor found on the surface of T-cells, bridging them together and activating the T-cells to kill the myeloma cells.
The binding affinity of elranatamab for BCMA and CD3 has been engineered to elicit potent T-cell mediated anti-myeloma activity.
In 2022, FDA granted Elranatamab a breakthrough drug designation.
仕様
サイズ：1 x 96 wells
Reactivity：Human
アプリケーション：ELISA,Immunoassay
Sensitivity：Please refer to the current IFU for the updated calibrator range and sensitivity.
